Market Tracker

09/28 5:48pm ET

Biomarin Pharmaceutical Inc (NASDAQ:BMRN)

96.03
Delayed Data
As of 4:14pm ET
 -1.02 / -1.05%
Today’s Change
62.12
Today|||52-Week Range
118.48
-8.33%
Year-to-Date
Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc
12:24pm / MotleyFool.com - Paid Partner Content
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Sep 20 / Zacks.com - Paid Partner Content
Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?
Sep 20 / MotleyFool.com - Paid Partner Content
 

Today’s Trading

Previous close97.05
Today’s open98.19
Day’s range94.42 - 98.19
Volume1,194,396
Average volume (3 months)1,689,222
Market cap$16.6B
Dividend yield--
Data as of 4:14pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)-16.30%
Earnings growth (this year)-275.23%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+16.29%
P/E ratioNM
Price/Sales19.22
Price/Book6.53

Competitors

 Today’s
change
Today’s
% change
INCYIncyte Corp+4.13+4.64%
PRGOPerrigo Company PLC+0.51+0.53%
MDVNMedivation Inc0.000.00%
VRTXVertex Pharmaceutica...-0.28-0.31%
Data as of 4:14pm ET, 09/28/2016

Financials

Next reporting dateOctober 20, 2016
EPS forecast (this quarter)-$0.39
Annual revenue (last year)$872.2M
Annual profit (last year)-$171.8M
Net profit margin-19.70%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Jean-Jacques Bienaimé
Chief Financial Officer &
Executive Vice President
Daniel K. Spiegelman
Corporate headquarters
San Rafael, California

Forecasts